Details of the Drug

General Information of Drug (ID: DM61TA4)

Drug Name
Arsenic trioxide
Synonyms
Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 197.841
Topological Polar Surface Area Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 3
ADMET Property
Metabolism
The drug is metabolized via the methyltransferases in the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7582 micromolar/kg/day [4]
Chemical Identifiers
Formula
As2O3
IUPAC Name
arsenic(3+);oxygen(2-)
Canonical SMILES
[O-2].[O-2].[O-2].[As+3].[As+3]
InChI
InChI=1S/2As.3O/q2*+3;3*-2
InChIKey
QTLQKAJBUDWPIB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
14888
CAS Number
1327-53-3
DrugBank ID
DB01169
TTD ID
D07VIK
VARIDT ID
DR00119

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inhibitor of nuclear factor kappa-B kinase beta (IKKB) TTJ3E9X IKKB_HUMAN Inhibitor [5], [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DTT IKBKB 5.74E-08 0.26 0.88
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 7.16E-01 -1.28E-02 -6.06E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Arsenic trioxide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Ivosidenib. Acute myeloid leukaemia [2A60] [35]
Midostaurin DMI6E0R Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Midostaurin. Acute myeloid leukaemia [2A60] [35]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Idarubicin. Acute myeloid leukaemia [2A60] [35]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Arn-509. Acute myeloid leukaemia [2A60] [35]
Gilteritinib DMWQ4MZ Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Gilteritinib. Acute myeloid leukaemia [2A60] [35]
Oliceridine DM6MDCF Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Oliceridine. Acute pain [MG31] [35]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Ivabradine. Angina pectoris [BA40] [36]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Bepridil. Angina pectoris [BA40] [35]
Bedaquiline DM3906J Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [35]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Posaconazole. Aspergillosis [1F20] [35]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Arsenic trioxide and Levalbuterol. Asthma [CA23] [37]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Arsenic trioxide and Pirbuterol. Asthma [CA23] [38]
Lisdexamfetamine DM6W8V5 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [35]
Clarithromycin DM4M1SG Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Clarithromycin. Bacterial infection [1A00-1C4Z] [35]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [39]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Retigabine. Behcet disease [4A62] [35]
Eribulin DM1DX4Q Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Eribulin. Breast cancer [2C60-2C6Y] [35]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Lapatinib. Breast cancer [2C60-2C6Y] [35]
Bosutinib DMTI8YE Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Bosutinib. Breast cancer [2C60-2C6Y] [35]
PF-04449913 DMSB068 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [35]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [38]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Arsenic trioxide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [37]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [38]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [38]
Panitumumab DMQPD1F Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Panitumumab. Colorectal cancer [2B91] [35]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Sevoflurane. Corneal disease [9A76-9A78] [35]
Probucol DMVZQ2M Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Probucol. Coronary atherosclerosis [BA80] [35]
Pasireotide DMHM7JS Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Pasireotide. Cushing syndrome [5A70] [35]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Osilodrostat. Cushing syndrome [5A70] [35]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Escitalopram. Depression [6A70-6A7Z] [40]
Clomipramine DMINRKW Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Clomipramine. Depression [6A70-6A7Z] [35]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [35]
Deutetrabenazine DMUPFLI Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Deutetrabenazine. Dystonic disorder [8A02] [35]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Solifenacin. Functional bladder disorder [GC50] [35]
Sunitinib DMCBJSR Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [35]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [41]
Lopinavir DMITQS0 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [35]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Polyethylene glycol. Irritable bowel syndrome [DD91] [42]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Phenolphthalein. Irritable bowel syndrome [DD91] [40]
Osimertinib DMRJLAT Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Osimertinib. Lung cancer [2C25] [35]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Selpercatinib. Lung cancer [2C25] [35]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Lumefantrine. Malaria [1F40-1F45] [43]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Halofantrine. Malaria [1F40-1F45] [44]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Hydroxychloroquine. Malaria [1F40-1F45] [35]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Vemurafenib. Melanoma [2C30] [35]
LGX818 DMNQXV8 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and LGX818. Melanoma [2C30] [35]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Panobinostat. Multiple myeloma [2A83] [35]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Siponimod. Multiple sclerosis [8A40] [43]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Fingolimod. Multiple sclerosis [8A40] [40]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Ozanimod. Multiple sclerosis [8A40] [45]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Romidepsin. Mycosis fungoides [2B01] [35]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Nilotinib. Myeloproliferative neoplasm [2A20] [35]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Dasatinib. Myeloproliferative neoplasm [2A20] [35]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Entrectinib. Non-small cell lung cancer [2C25] [35]
Polythiazide DMCH80F Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Polythiazide. Oedema [MG29] [35]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Levomethadyl Acetate. Opioid use disorder [6C43] [36]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Lofexidine. Opioid use disorder [6C43] [35]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Rucaparib. Ovarian cancer [2C73] [35]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Triclabendazole. Parasitic worm infestation [1F90] [35]
Pimavanserin DMR7IVC Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Pimavanserin. Parkinsonism [8A00] [35]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Macimorelin. Pituitary gland disorder [5A60-5A61] [46]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Lefamulin. Pneumonia [CA40] [35]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Degarelix. Prostate cancer [2C82] [35]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and ABIRATERONE. Prostate cancer [2C82] [35]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Enzalutamide. Prostate cancer [2C82] [35]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Levomepromazine. Psychotic disorder [6A20-6A25] [35]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Quetiapine. Schizophrenia [6A20] [35]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Arsenic trioxide and Aripiprazole. Schizophrenia [6A20] [43]
Iloperidone DM6AUFY Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Iloperidone. Schizophrenia [6A20] [35]
Paliperidone DM7NPJS Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Paliperidone. Schizophrenia [6A20] [35]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Amisulpride. Schizophrenia [6A20] [35]
Asenapine DMSQZE2 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Asenapine. Schizophrenia [6A20] [35]
LEE011 DMMX75K Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and LEE011. Solid tumour/cancer [2A00-2F9Z] [35]
Vandetanib DMRICNP Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [35]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [35]
Pitolisant DM8RFNJ Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Pitolisant. Somnolence [MG42] [35]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [35]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Lenvatinib. Thyroid cancer [2D10] [35]
Cabozantinib DMIYDT4 Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Cabozantinib. Thyroid cancer [2D10] [35]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [35]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Arsenic trioxide and Propafenone. Ventricular tachyarrhythmia [BC71] [35]
Flecainide DMSQDLE Major Increased risk of ventricular arrhythmias by the combination of Arsenic trioxide and Flecainide. Ventricular tachyarrhythmia [BC71] [35]
⏷ Show the Full List of 84 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 078729.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 European Public Assessment Report: Trisenox
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
6 Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J. 2002 Jan-Feb;8(1):12-25.
7 MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
8 Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26.
9 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
10 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
11 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
12 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
13 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
14 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
15 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
16 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
17 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
18 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
19 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
21 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
22 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26 The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
27 The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653.
28 Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
29 I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
30 Company report (Millennium)
31 Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
32 Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
33 UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65.
34 Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
35 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
36 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
38 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
39 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
40 Canadian Pharmacists Association.
41 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
42 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
43 Cerner Multum, Inc. "Australian Product Information.".
44 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
45 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
46 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.